Autor: "Vogl UM" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs
Autorzy:: Turco F
Gillessen S
Cathomas R
Buttigliero C
Vogl UM; Pokaż więcej
Temat:: prostate cancer – castration resistant prostate cancer – non metastatic castration resistant prostate cancer – metastatic castration resistant prostate cancer - treatment landscape in prostate cancer
Diseases of the genitourinary system. Urology
RC870-923
Źródło:: Research and Reports in Urology, Vol Volume 14, Pp 339-350 (2022)
Opis pliku:: electronic resource
Relacje:: https://www.dovepress.com/treatment-landscape-for-patients-with-castration-resistant-prostate-ca-peer-reviewed-fulltext-article-RRU; https://doaj.org/toc/2253-2447
Dostęp URL:: https://doaj.org/article/a3e5fadf09be437b8e6a570f7d3851d5 Link otwiera się w nowym oknie

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 2.

Tytuł:: Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
Autorzy:: Schmidinger M
Vogl UM
Bojic M
Lamm W
Heinzl H
Haitel A
Clodi M
Kramer G
Zielinski CC
Schmidinger, Manuela
Vogl, Ursula M
Bojic, Marija
Lamm, Wolfgang
Heinzl, Harald
Haitel, Andrea
Clodi, Martin
Kramer, Gero
Zielinski, Christoph C; Pokaż więcej
Źródło:: Cancer (0008543X); 2/1/2011, Vol. 117 Issue 3, p534-544, 11p

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 3.

Tytuł:: Antiandrogens as Therapies for COVID-19: A Systematic Review.
Autorzy:: Cani M; Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.; Oncology Unit, Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, 10043 Orbassano, Italy.
Epistolio S; Laboratory of Genetics and Molecular Pathology, Institute of Pathology, Ente Ospedaliero Cantonale (EOC), 6600 Locarno, Switzerland.
Dazio G; Laboratory of Genetics and Molecular Pathology, Institute of Pathology, Ente Ospedaliero Cantonale (EOC), 6600 Locarno, Switzerland.
Modesti M; Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.; Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, 50134 Florence, Italy.
Salfi G; Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland.
Pedrani M; Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, 20122 Milan, Italy.
Isella L; Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Gillessen S; Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.; Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland.
Vogl UM; Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Tortola L; Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Treglia G; Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland.; Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.; Faculty of Biology and Medicine, University of Lausanne, 1005 Lausanne, Switzerland.
Buttigliero C; Oncology Unit, Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, 10043 Orbassano, Italy.
Frattini M; Laboratory of Genetics and Molecular Pathology, Institute of Pathology, Ente Ospedaliero Cantonale (EOC), 6600 Locarno, Switzerland.
Pereira Mestre R; Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland.; Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland.; Clinical Research Unit, myDoctorAngel, 6934 Bioggio, Switzerland.; Pokaż więcej
Źródło:: Cancers [Cancers (Basel)] 2024 Jan 10; Vol. 16 (2). Date of Electronic Publication: 2024 Jan 10.
Typ publikacji:: Journal Article; Review

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer.
Autorzy:: Calabrese M; Department of Oncology, University of Turin, AOU San Luigi Gonzaga, 10043 Orbassano, Italy.
Saporita I; Department of Oncology, University of Turin, AOU San Luigi Gonzaga, 10043 Orbassano, Italy.
Turco F; Department of Oncology, University of Turin, AOU San Luigi Gonzaga, 10043 Orbassano, Italy.; Ente Ospedaliero Cantonale-Istituto Oncologico della Svizzera Italiana, 6500 Bellinzona, Switzerland.
Gillessen S; Ente Ospedaliero Cantonale-Istituto Oncologico della Svizzera Italiana, 6500 Bellinzona, Switzerland.; Department of Medical Oncology, Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland.
Castro E; Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.
Vogl UM; Ente Ospedaliero Cantonale-Istituto Oncologico della Svizzera Italiana, 6500 Bellinzona, Switzerland.
Di Stefano RF; Department of Oncology, University of Turin, AOU San Luigi Gonzaga, 10043 Orbassano, Italy.
Carfì FM; Department of Oncology, University of Turin, AOU San Luigi Gonzaga, 10043 Orbassano, Italy.
Poletto S; Department of Oncology, University of Turin, AOU San Luigi Gonzaga, 10043 Orbassano, Italy.
Farinea G; Department of Oncology, University of Turin, AOU San Luigi Gonzaga, 10043 Orbassano, Italy.
Tucci M; Department of Medical Oncology, Cardinal Massaia Hospital, 14100 Asti, Italy.
Buttigliero C; Department of Oncology, University of Turin, AOU San Luigi Gonzaga, 10043 Orbassano, Italy.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2023 Dec 20; Vol. 25 (1). Date of Electronic Publication: 2023 Dec 20.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Receptors, Androgen*/genetics
Prostatic Neoplasms*/drug therapy
Adenosine*
Polymers*
Male ; Humans ; Synthetic Lethal Mutations ; Diphosphates ; Ribose ; Androgen Receptor Antagonists

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland.
Autorzy:: Çakar E; OPEN Health, Rotterdam, The Netherlands.
Oniangue-Ndza C; Bristol Myers Squibb SA, Hinterbergstrasse 16, 6330, Steinhausen, Switzerland. .
Schneider RP; Bristol Myers Squibb SA, Hinterbergstrasse 16, 6330, Steinhausen, Switzerland.
Klijn SL; Bristol Myers Squibb, Princeton, NJ, USA.
Vogl UM; Istituto Oncologico della Svizzera Italiana (IOSI), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
Rothermundt C; Klinik für Medizinische Onkologie und Hämatologie, Kantonsspital St. Gallen, St. Gallen, Switzerland.
May JR; Bristol Myers Squibb, Uxbridge, UK.; Pokaż więcej
Źródło:: PharmacoEconomics - open [Pharmacoecon Open] 2023 Jul; Vol. 7 (4), pp. 567-577. Date of Electronic Publication: 2023 Feb 09.
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: How Does Environmental and Occupational Exposure Contribute to Carcinogenesis in Genitourinary and Lung Cancers?
Autorzy:: Cani M; Oncology Unit, Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, 10043 Orbassano, Italy.
Turco F; Oncology Unit, Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, 10043 Orbassano, Italy.; Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Butticè S; Oncology Unit, Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, 10043 Orbassano, Italy.
Vogl UM; Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Buttigliero C; Oncology Unit, Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, 10043 Orbassano, Italy.
Novello S; Oncology Unit, Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, 10043 Orbassano, Italy.
Capelletto E; Oncology Unit, Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, 10043 Orbassano, Italy.; Pokaż więcej
Źródło:: Cancers [Cancers (Basel)] 2023 May 19; Vol. 15 (10). Date of Electronic Publication: 2023 May 19.
Typ publikacji:: Journal Article; Review

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Prostate Cancer and Sleep Disorders: A Systematic Review.
Autorzy:: Sparasci D; Sleep Medicine Unit, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), 6900 Lugano, Switzerland.
Napoli I; Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.; Radiation Oncology Unit, Department of Biomedical, Dental Science, Morphological and Functional Imaging, University Hospital Messina, 98122 Messina, Italy.
Rossi L; Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Pereira-Mestre R; Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland.
Manconi M; Sleep Medicine Unit, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), 6900 Lugano, Switzerland.; Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland.; Department of Neurology, University Hospital Inselspital, 3010 Bern, Switzerland.
Treglia G; Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland.; Academic Education, Research and Innovation Area, General Directorate, Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.; Faculty of Biology and Medicine, University of Lausanne, 1005 Lausanne, Switzerland.
Marandino L; Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.; Department of Medical Oncology, IRCCS San Raffaele Hospital, 20132 Milan, Italy.
Ottaviano M; Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.; Department of Clinical Medicine and Surgery, University Federico II of Naples, 80138 Naples, Italy.
Turco F; Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.; Department of Oncology, Division of Medical Oncology, University of Turin San Luigi Gonzaga Hospital, Regione Gonzole, 10043 Orbassano, Italy.
Mangan D; Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.; Division of Population Health, University of Manchester, Manchester M13 9PL, UK.
Gillessen S; Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.; Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland.
Vogl UM; Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.; Pokaż więcej
Źródło:: Cancers [Cancers (Basel)] 2022 Mar 31; Vol. 14 (7). Date of Electronic Publication: 2022 Mar 31.
Typ publikacji:: Journal Article; Review

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives.
Autorzy:: Rebuzzi SE; Medical Oncology Unit, Ospedale San Paolo, 17100 Savona, Italy.; Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, 16132 Genova, Italy.
Rescigno P; Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
Catalano F; Medical Oncology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Mollica V; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Vogl UM; Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Marandino L; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, 20132 Milan, Italy.
Massari F; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Pereira Mestre R; Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland.
Zanardi E; Academic Unit of Medical Oncology, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Signori A; Department of Health Sciences (DISSAL), University of Genova, 16132 Genova, Italy.
Buti S; Medical Oncology Unit, University Hospital of Parma, 43100 Parma, Italy.; Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.
Bauckneht M; Department of Health Sciences (DISSAL), University of Genova, 16132 Genova, Italy.; Nuclear Medicine, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Gillessen S; Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.; Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), 6900 Lugano, Switzerland.; Division of Cancer Sciences, University of Manchester, Manchester M13 9PL, UK.
Banna GL; Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
Fornarini G; Medical Oncology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.; Pokaż więcej
Źródło:: Cancers [Cancers (Basel)] 2022 Feb 28; Vol. 14 (5). Date of Electronic Publication: 2022 Feb 28.
Typ publikacji:: Journal Article; Review

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something?
Autorzy:: Ottaviano M; Oncology Unit, Ospedale del Mare, 80147 Naples, Italy.; CRCTR Coordinating Rare Tumors Reference Center of Campania Region, 80131 Naples, Italy.; IOSI (Oncology Institute of Southern Switzerland), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Giunta EF; Oncology Unit, Department of Precision Medicine, Università Degli Studi Della Campania Luigi Vanvitelli, 80131 Naples, Italy.
Rescigno P; Interdisciplinary Group for Translational Research and Clinical Trials, Urological Cancers (GIRT-Uro), Candiolo Cancer Institute, FPO-IRCCS, Candiolo, 10160 Turin, Italy.
Pereira Mestre R; IOSI (Oncology Institute of Southern Switzerland), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Marandino L; IOSI (Oncology Institute of Southern Switzerland), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Tortora M; CRCTR Coordinating Rare Tumors Reference Center of Campania Region, 80131 Naples, Italy.
Riccio V; Department of Clinical Medicine and Surgery, Università degli studi di Napoli Federico II, 80131 Naples, Italy.
Parola S; Department of Clinical Medicine and Surgery, Università degli studi di Napoli Federico II, 80131 Naples, Italy.
Casula M; Institute of Genetics and Biomedical Research (IRGB), National Research Council (CNR), 07100 Sassari, Italy.
Paliogiannis P; Departments of Biomedical Sciences and Medical, Surgical, Experimental Sciences, University of Sassari, 07100 Sassari, Italy.
Cossu A; Departments of Biomedical Sciences and Medical, Surgical, Experimental Sciences, University of Sassari, 07100 Sassari, Italy.
Vogl UM; IOSI (Oncology Institute of Southern Switzerland), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Bosso D; Oncology Unit, Ospedale del Mare, 80147 Naples, Italy.
Rosanova M; Oncology Unit, Ospedale del Mare, 80147 Naples, Italy.
Mazzola B; Department of Urology, Ente Ospedaliero Cantonale (EOC), 6600 Locarno, Switzerland.
Daniele B; Oncology Unit, Ospedale del Mare, 80147 Naples, Italy.
Palmieri G; Institute of Genetics and Biomedical Research (IRGB), National Research Council (CNR), 07100 Sassari, Italy.; Departments of Biomedical Sciences and Medical, Surgical, Experimental Sciences, University of Sassari, 07100 Sassari, Italy.
Palmieri G; CRCTR Coordinating Rare Tumors Reference Center of Campania Region, 80131 Naples, Italy.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2021 Jul 02; Vol. 22 (13). Date of Electronic Publication: 2021 Jul 02.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Genes, p53*
Neoplasms, Germ Cell and Embryonal/*metabolism
Tumor Suppressor Protein p53/*metabolism
Antineoplastic Agents/therapeutic use ; Cisplatin/therapeutic use ; Drug Resistance, Neoplasm ; Humans ; Neoplasms, Germ Cell and Embryonal/drug therapy ; Neoplasms, Germ Cell and Embryonal/genetics ; Neoplasms, Germ Cell and Embryonal/secondary ; Tumor Suppressor Protein p53/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Autorzy:: Vogl UM; Department of Internal Medicine II, Oncology, Barmherzige Schwestern Wien, Stumpergasse 13, 1060, Vienna, Austria. ursula.vogl@bhs.at.
Andalibi H; Department of Internal Medicine II, Oncology, Barmherzige Schwestern Wien, Stumpergasse 13, 1060, Vienna, Austria.
Klaus A; Department of Surgery, Barmherzige Schwestern Wien, Vienna, Austria.
Vormittag L; Department of Internal Medicine I, Oncology, Sankt Josef Krankenhaus, Vienna, Austria.
Schima W; Department of Diagnostic and Interventional Radiology, Barmherzige Schwestern Krankenhaus Wien, Goettlicher Heiland Krankenhaus and Sankt Josef Krankenhaus, Vienna, Austria.
Heinrich B; Department of Internal Medicine I, Oncology, Sankt Josef Krankenhaus, Vienna, Austria.
Kafka A; Department of Internal Medicine I, Oncology, Sankt Josef Krankenhaus, Vienna, Austria.
Winkler T; Department of Internal Medicine I, Oncology, Sankt Josef Krankenhaus, Vienna, Austria.
Öhler L; Department of Internal Medicine II, Oncology, Barmherzige Schwestern Wien, Stumpergasse 13, 1060, Vienna, Austria.; Department of Internal Medicine I, Oncology, Sankt Josef Krankenhaus, Vienna, Austria.; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2019 Jan 08; Vol. 19 (1), pp. 28. Date of Electronic Publication: 2019 Jan 08.
Typ publikacji:: Journal Article
MeSH Terms:: Adenocarcinoma/*drug therapy
Albumins/*administration & dosage
Fluorouracil/*administration & dosage
Leucovorin/*administration & dosage
Organometallic Compounds/*administration & dosage
Paclitaxel/*administration & dosage
Pancreatic Neoplasms/*drug therapy
Adenocarcinoma/pathology ; Adult ; Aged ; Aged, 80 and over ; Albumins/adverse effects ; Antineoplastic Combined Chemotherapy Protocols ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Deoxycytidine/analogs & derivatives ; Drug Combinations ; Female ; Fluorouracil/adverse effects ; Humans ; Irinotecan ; Leucovorin/adverse effects ; Male ; Middle Aged ; Organometallic Compounds/adverse effects ; Oxaliplatin ; Paclitaxel/adverse effects ; Pancreatic Neoplasms/pathology ; Progression-Free Survival ; Retrospective Studies ; Treatment Outcome ; Gemcitabine